Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.02 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Ross Stores raises 2026 outlook after strong second-quarter results